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Abstract
Background: IPT with or without concomitant administration of ART is a proven intervention to prevent tuberculosis
among PLHIV. However, there are few data on the routine implementation of this intervention and its effectiveness in
settings with limited resources.
Objectives: To measure the level of uptake and effectiveness of IPT in reducing tuberculosis incidence in a cohort of PLHIV
enrolled into HIV care between 2007 and 2010 in five hospitals in southern Ethiopia.
Methods: A retrospective cohort analysis of electronic patient database was done. The independent effects of no
intervention, ‘‘IPT-only,’’ ‘‘IPT-before-ART,’’ ‘‘IPT-and-ART started simultaneously,’’ ‘‘ART-only,’’ and ‘‘IPT-after-ART’’ on TB
incidence were measured. Cox-proportional hazards regression was used to assess association of treatment categories with
TB incidence.
Results: Of 7,097 patients, 867 were excluded because they were transferred-in; a further 823 (12%) were excluded from the
study because they were either identified to have TB through screening (292 patients) or were on TB treatment (531).
Among the remaining 5,407 patients observed, IPT had been initiated for 39% of eligible patients. Children, male sex,
advanced disease, and those in Pre-ART were less likely to be initiated on IPT. The overall TB incidence was 2.6 per 100
person-years. As compared to those with no intervention, use of ‘‘IPT-only’’ (aHR= 0.36, 95% CI = 0.19–0.66) and ‘‘ART-only’’
(aHR= 0.32, 95% CI = 0.24–0.43) were associated with significant reduction in TB incidence rate. Combining ART and IPT had
a more profound effect. Starting IPT-before-ART (aHR= 0.18, 95% CI = 0.08–0.42) or simultaneously with ART (aHR= 0.20,
95% CI = 0.10–0.42) provided further reduction of TB at ,80%.
Conclusions: IPT was found to be effective in reducing TB incidence, independently and with concomitant ART, under
programme conditions in resource-limited settings. The level of IPT provision and effectiveness in reducing TB was
encouraging in the study setting. Scaling up and strengthening IPT service in addition to ART can have beneficial effect in
reducing TB burden among PLHIV in settings with high TB/HIV burden.
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Introduction
The TB/HIV syndemic is a global public health challenge
accounting for nearly 25% of all HIV-associated deaths [1]. Of 8.7
million estimated incident tuberculosis (TB) cases in 2011, about
13% were among people living with HIV (PLHIV) [1]. The
African region, with 80% of the estimated HIV-infected TB cases,
bears the brunt of the epidemic [1]. Ethiopia has the dual
distinction of being a high TB burden country with incidence of
277 TB cases per 100,000 people per year [2] as well as a high
HIV burden country with adult (15–49) HIV prevalence of 1.5%
[3]. The prevalence of HIV among TB patients was estimated at
8% [1].
To reduce the burden of TB among PLHIV, the World Health
Organization (WHO) recommends Intensified Case Finding (ICF),
Isoniazid Preventive Therapy (IPT), Infection control, and early
initiation of antiretroviral therapy (ART) [4]. Of these, ART is the
most potent and widely implemented TB preventive intervention
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among PLHIV [4]. Although anti-retroviral drugs lower the risk of
TB through immune reconstitution, the risk remains much higher
than in HIV-uninfected individuals despite achievement of good
CD4 cell recovery, emphasizing the need to implement other
preventive interventions such as IPT. Observational studies done
in Brazil and South Africa have shown that the combined effect of
ART and IPT in preventing TB among PLHIV is significantly
higher compared to using only ART [5–7]. Despite strong
recommendations globally, the uptake of IPT has been limited
due to difficulties in excluding active TB, added pill burden for
patients, side effects, poor adherence to IPT, and concerns about
development of drug resistance. In a review done by the WHO
guidelines group, adherence for IPT ranged from 34–98% [4].
One study in Ethiopia demonstrated the effectiveness of IPT in
reducing TB burden among PLHIV [8]. But, there is no published
evidence on uptake and completion rates of IPT among PLHIV in
Ethiopia, or its effectiveness in reducing TB incidence in
combination with ART, when implemented under routine
programmatic settings. There are also uncertainties regarding
timing of IPT initiation in relation to ART. The WHO has
identified these issues as priority areas for operational research [4].
In this study, we assessed the uptake and effectiveness of IPT in
reducing TB incidence, when used alone or in combination with
ART and the effect of timing of initiation of IPT in relation to
initiation of ART in a population of PLHIV in Southern Ethiopia.
Methods
Ethics Considerations
Approval was obtained from the National Research Ethics
Review Committee of Ethiopia. Furthermore, the original data
collection for the pre-existing, de-identified/de-linked datasets
used for this study was given a non-research determination and
subsequent approval for secondary analysis by IRBs of Centers for
Disease Control and Prevention (CDC) and Johns Hopkins
University School of Public Health (JHSPH). Additional approval
was obtained from the Ethics Advisory Group of the International
Union against Tuberculosis and Lung Disease (IUATLD).
Informed consent was not obtained since data was de-identified/
de-linked before analysis.
Study Design and Setting
This is a cohort study based on a secondary analysis of an
electronic database of patients under care at five HIV/ART clinics
in the Southern Nations, Nationalities and People’s Region
(SNNPR).The SNNPR, south of the Ethiopian capital Addis
Ababa, has a population of about 17 million [9]. According to the
latest Demographic and Health Survey of Ethiopia, the HIV
prevalence for the region was estimated at 0.9% in 2011 [3].
Health services in the region are provided by 14 governmental, six
non- government hospitals and 180 health centers. All public
hospitals have provided ART and IPT for eligible patients based
on the national ART and TB/HIV guidelines since 2005 and
2008 respectively. Eligibility for ART was based on the following
criteria: all WHO stage 4 clients, WHO stage 3 clients with CD4#
350 and WHO stage 1 or 2 with CD4#200. In the absence of
CD4 testing, WHO stages 3 and 4 were eligible for ART. The first
line ARV regimens used were according to national and
international guidelines [10].
At each visit all HIV infected clients were screened for TB,
using WHO recommended symptom-based screening, and symp-
tomatic patients were evaluated by diagnostic tests (sputum smear
microscopy, chest radiography, clinical evaluation) and with
treatment provided where indicated [11]. Clients screening
negative for TB and without contraindications were eligible to
start IPT at any time. Tuberculin skin test (TST) was not done for
patients before IPT initiation. IPT was provided for a period of 6
months at a dosage of 300 mg/day for adults and 5–10 mg/kg/
day for children [11]. Patients collected their drugs every month
until the treatment course was completed. Patients on IPT were
monitored monthly for development of active TB, adherence to
treatment and adverse drug reactions. All patient details were
documented by trained and supervised health care workers,
standardized to maintain accuracy [10,12] and all services were
provided free to the patients.
Study Period and Population
The sampling frame constituted all 20 hospitals in SNNP
region. All PLHIV newly enrolled in chronic HIV care in five
randomly selected hospitals of SNNP region of Ethiopia between
September 2007 and August 2010 constituted the study popula-
tion. All cases of prevalent TB (TB cases already on treatment at
the time of enrolment into HIV care and those diagnosed within
one month of enrolment) were excluded from the cohort.
Variables and Source of Data
The primary outcome variable was ‘incident TB’, defined as
any new TB case that was diagnosed after one month of enrolment
into HIV care. The primary exposures of interest were initiation of
IPT and/or ART. We extracted data on these and other key
covariates from the existing electronic database which included
baseline WHO clinical stage, baseline CD4 count, age, sex, history
of cotrimoxazole use, IPT completion and duration of ART
intake. The data correspond to data on national forms for care of
patients with HIV. The data were collected to support clinical
decision-making and reporting to the government. All patients
enrolling in HIV care at the clinic were registered in the database.
Demographic information and other key milestones, like date of
enrollment to care, date of ART initiation, date of IPT initiation,
date of patient visit, and date of tuberculosis treatment initiation
were recorded for each patient.
Data Analysis
Epi Info statistical software Version 3.4 (United States Centers
for Disease Control and Prevention, Atlanta, GA) and MS Access
2007 were used to clean and analyze the data. Person-time
incidence rates, incidence rate ratios and hazard ratios were
calculated using Stata statistical software Version 12. Person-time
at risk of TB was accrued from the date of enrolment in chronic
care until death, transfer to other facility, loss to follow-up (LTFU),
appearance of incident TB, or last visit. Any patient over four
weeks late for a scheduled appointment who failed to return to the
ART programme and could not be located by ‘‘case managers’’
was classified as LTFU. The following two variables were treated
as time-updated variables: IPT intake, with patients accruing
person time in IPT groups after time of IPT initiation; ART
intake, with patients accruing person time in ART groups after
time of ART initiation. Based on this, patients were divided into
six exposure categories to assess the combined effect of IPT intake,
and ART treatment. ‘No intervention’ period when neither IPT
nor ART were initiated; ‘IPT only’ period when IPT was the only
treatment received; ‘ART only’ period when ART was the only
treatment received; ‘IPT before ART’ period when ART was
taken after IPT initiation; ‘IPT & ART simultaneously’ when IPT
was initiated within two weeks of ART initiation; and ‘IPT after
ART’ period when IPT was taken after ART initiation’. A more
elaborate pictorial description of this time splitting process is found
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in figure S1. Similar procedure was followed to assess the overall
effect of IPT completion and duration of ART treatment.
Missing values for baseline CD4 (22%) and WHO stage (10%)
were calculated by multiple imputation methods using multivariate
normal (mvn) regression. Twenty five data sets were generated.
Site, year of enrolment, sex, age, cotrimoxazole use, ART status,
INH use, and incident TB were used as regular variables to impute
them. Survival methods were used to assess the relationship of
independent variables listed above to incident TB. Participants
were censored from the risk set after the first new TB diagnosis -
multiple outcomes were not allowed. We fit a multivariable Cox
proportional hazards regression model. Stratification was used to
correct for effect of within-group correlation at site level on the
relationship between independent and dependent variables. We
constructed the model using stepwise techniques, adding one
independent variable at a time to the model. The decision rule for
addition of a variable to the model was if significance was less than
0.05, and the rule for removal was at significance more than 0.1. P
values for risk ratios were calculated using chi-square test.
A secondary analysis was done taking the definition of incident
TB as that occurring two months after enrolment. Finally,
sensitivity analysis was done to assess if baseline characteristic of
patients not on follow-up differed from those on follow-up and to
see the effect of IPT on TB incidence, assuming 25% of randomly
selected patients who were lost to follow-up or dead developed TB
at time of censoring. The final dataset and program codes to




Of the 7097 patients, 867 were excluded because they were
transferred in; a further 823 (12%) were excluded from the study
because they were either identified to have TB through screening
(292 patients) or were on TB treatment (531). Thus, there were
5407 patients studied. (Figure 1)
Median age was 30 years (range, 0.16–82) and the median
follow-up duration was two years with inter-quartile range (IQR)
of 0.2–4 years. Most of the patients were adults more than 14 years
of age (91%) and the proportion of females was 57%. (Table 1)
Among patients on ART, patients with higher baseline CD4
count, and WHO disease stage 1 or 2 were more likely to have
active follow-up at the end of the study (data not shown). Median
baseline CD4 count was lowest for the ‘ART only’ group (152/
mm3) followed by ‘IPT after ART’ (160/mm3), and ‘IPT and
ART Simultaneously’ (187/mm3). Higher baseline CD4 counts
were recorded for the ‘IPT only’ group (375/mm3) followed by
‘IPT before ART’ groups (242/mm3) and ‘no intervention’ group
(216/mm3).
IPT Initiation and Completion
IPT was initiated for 2131 (39%) patients, and 44% of them
initiated IPT during Pre-ART care (Tables 1 and 2). Adults,
women, those having CD4 count more than 100, those with earlier
WHO disease stage and those having initiated ART were more
likely to receive IPT. There was documented completion of IPT in
24% of those who started treatment. There were no statistically
significant associations between IPT completion and other
covariates.
Incident Tuberculosis
There were 295 incident TB cases in this study cohort during
11,290 person-years (PY) of observation, making the overall TB
incidence rate 2.6 per 100 PY of follow-up (95% CI: 2.3–2.9)
(Table 3). The TB incidence rate in those who took IPT was 0.7
per 100 PY and 6.1 per 100 PY for those who did not (IRR: 0.11;
95% CI: 0.08–0.15 before controlling for effect of ART). This
protective effect of IPT intake persisted whether IPT completion
was documented or not.
The first six months on ART represented the period with the
highest risk (TB incidence 8.0 per 100 PY; 95% CI: 6.0–10),
followed by Pre-ART period (TB incidence 3.9 per 100 PY; 95%
CI: 3.3–4.6). After the first 6 months it decreased progressively
with increase in length of time on ART. TB incidence was higher
among ‘ART only’ and ‘No intervention’ treatment categories as
compared to ‘IPT only’, ‘IPT before ART’, ‘IPT & ART
simultaneously’ or ‘IPT after ART’. Patients who took IPT and
were eventually started on ART or those who started both
simultaneously had lower risk of developing TB as compared to
those who took ART only. The combined effect of IPT and ART
when started at the same time reduced TB incidence by 57%
(IRR: 0.43; 95%CI 0.18–0.86) as compared to those who took
ART only (Table 3).
Cox Proportional Hazards Modeling
During bivariable analysis, male sex, cotrimoxazole use,
advanced disease stage, and having a lower CD4 count were
associated with increased relative hazard for developing TB
(Table 3). On the other hand, being on IPT (irrespective of
completion status), and taking ART for longer duration were each
associated with lower relative hazard of developing TB. After
controlling for sex, WHO stage, baseline CD4, and cotrimoxazole
use, ART intake was protective against TB, and more so with
greater duration of ART as compared to those not on ART. In
bivariable analysis, all treatment categories showed protective
effect but it was higher for ‘IPT only’ (HR 0.24, 95% CI 0.13–
0.44), ‘IPT before ART’ (0.25, 95% CI 0.11–0.59), ‘IPT & ART
simultaneously’ (HR 0.36; 95% CI 0.17–0.74) and ‘IPT after
ART’ (HR 0.19, 95% CI 0.11–0.34). After controlling for sex,
WHO stage, baseline CD4, and cotrimoxazole use, the ‘ART
only’ group (aHR 0.32, 95% CI 0.24–0.43) had higher protective
effect as well.
In the ‘IPT after ART’ group, TB incidence in the first six
months after ART initiation was 0.2 per 100 PY as compared to
those who were started on ART only which was at 6.2 per 100 PY.
The median time for IPT initiation for the ‘IPT after ART’ group
was nine months (IQR-3 months to 1.6 years).
Hazard ratios were calculated taking the definition of incident
TB to be new TB disease diagnosed after two months from
enrolment and the results were similar to those of the original
analysis. Sensitivity analysis was also done taking those started on
ART and assuming 25% of those lost to follow-up or dead
developed TB. IPT was still protective of TB (Table 4). The
percentages of patients lost to follow-up or dead among ‘IPT
before ART’, ‘ART only’, ‘IPT and ART simultaneously’, and
‘IPT after ART’ treatment groups were 9%, 39%, 17%, and 9%
respectively. The overall lost or death among ART patients was
24%.
Discussion
Over a third of PLHIV received IPT and its use was associated
with 65% reduction in tuberculosis occurrence in patients who had
not yet started ART. On the other hand, using only ART was
associated with 68% reduction in TB incidence. The effect of ART
use was directly proportional to the duration of treatment. Despite
that, TB incidence among patients on ART for more than three
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and a half years remained about four times as high as the current
estimate for the general population of Ethiopia which is 240 per
100,000 per year [2]. Combining IPT and ART resulted in further
reduction in TB incidence, reaffirming the synergistic role of the
two interventions. Timing of IPT initiation relative to ART
initiation did not make any difference in reduction of TB
incidence. Taking IPT before starting ART was associated with
82% reduction in TB incidence while starting IPT & ART
simultaneously resulted in 80% reduction. TB incidence was much
higher during the first six months of ART suggesting a possibility
of TB immune reconstitution inflammatory syndrome (IRIS)
which occurs in the face of very low CD4 count [13]. In the study
cohort, 40% of TB cases diagnosed in this period had CD4 below
100, supporting the aforementioned premise.
The protective effect of ART and IPT was similar to what was
previously reported in Ethiopia [8,14].The protective effect
obtained from combining ART and IPT including the beneficial
effect of starting IPT before ART is well documented in the studies
done in South Africa and Brazil [5,6]. Significant TB incidence
reduction among patients who started IPT and ART simulta-
neously was a new finding.
The protective effect of initiating IPT after starting ART, which
was at 92%, should not be confused with this being the best option
to prevent TB in the first six months. This group of patients was
actually low risk for TB to begin with. TB incidence for this group
prior to IPT initiation but after ART was 0.2 per 100 PY as
compared to those who took ART only at 6.2 per 100 PY. Patients
in the ‘IPT after ART’ group survived initial treatment period
without experiencing TB and thus were likely to have been
healthier overall. So, a policy offering IPT after ART initiation
and after the risky period of TB has passed allows those at risk for
it to develop TB disease and would benefit only the minority who
were not at risk for TB in the first place. What would be rational is
to initiate IPT before ART if possible or simultaneously with
ART. This would benefit all patients but particularly those at risk
for TB IRIS in the first six months. Of course, IPT should be
offered if for some reason it was not initiated during these periods
because it would further decrease TB.
Figure 1. Cohort profile of study population, SNNP region, Ethiopia, September 2007 to August 2010. Of 7,097 patients enrolled in
chronic HIV care, 5,407 were eligible for analysis contributing a total of 11,290 PY of follow-up. These were further classified into six treatment
categories based on the combination of treatment received, IPT and/or ART, as well as the timing of IPT initiation with respect to ART. There were 295
incident TB cases diagnosed in the study period. IPT-Isoniazid Preventive Therapy; ART-antiretroviral therapy; TB-Tuberculosis; HIV-Human
Immunodeficiency virus; PY-person year. * ‘No IPT NO ART’ group is equivalent to no intervention group.
doi:10.1371/journal.pone.0104557.g001
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TST-positive patients benefit the most from IPT as compared to
those who are TST- negative [4]. In studies where TST status was
not determined results were mixed with some showing protective
effect and others not [4]. Ethiopia is a high TB burden country
with TST positivity among the general population reaching up to
66% [4,15]. In this study TST status was not determined, yet the
Table 1. Characteristics of HIV infected patients in chronic HIV care in SNNP region, Ethiopia, September 2007 to August 2010.
Category Sub-category Number (%)
Age (years) ,15 475 (9)
15–50 4683 (87)
.50 249 (5)
Sex Female 3095 (57)
Male 2312 (43)
WHO Stage Stage 1 & 2 3182 (59)
Stage 3 & 4 2225 (41)
CPT initiation Yes 3926 (73)
No 1481 (27)




IPT intake Yes 2131 (39)
No 3276 (61)
Timing of IPT initiation* Before ART initiation 939 (44)
After ART initiation 1192 (56)
ART initiation Yes 3183 (59)
No 2224 (41)
*among those who initiated IPT (n = 2131); IPT-Isoniazid Preventive Therapy; ART-antiretroviral therapy; CPT-Cotrimoxazole Preventive Therapy; WHO-World Health
Organization; HIV-Human Immunodeficiency virus.
doi:10.1371/journal.pone.0104557.t001
Table 2. Characteristics of HIV infected patients in Chronic HIV care who took IPT in SNNP region, Ethiopia, September 2007 to
August 2010.
Category Sub-category Total Took IPT, n (%) RR (95% CI) P value
Total 5407 2131 (39)
Age (years) ,15 475 125 (26) 1.0
15–50 4683 1898 (41) 1.54 (1.34–1.77) ,0.001
.50 249 108 (43) 1.65 (1.34–2.03) ,0.001
Sex Female 3095 1279 (41) 1.0
Male 2312 852 (37) 0.89 (0.83–0.95) ,0.001
WHO Stage Stage 1 and 2 3182 1318 (41) 1.0
Stage 3 and 4 2225 813 (37) 0.88 (0.82–0.94) ,0.001
CPT initiation Yes 3926 1751 (45) 1.0
No 1481 380 (26) 0.58 (0.52–0.63) ,0.001
Baseline CD4 (count/mm3) ,100 1002 345 (34) 1.0
100–199 1545 635 (41) 1.19 (1.08–1.33) 0.001
200–349 1590 638 (40) 1.17 (1.05–1.29) 0.004
$350 1270 513 (40) 1.17 (1.05–1.31) 0.004
ART initiation Yes 3183 1606 (50) 1.0
No 2224 525 (24) 0.47 (0.43–0.51) ,0.001
IPT-Isoniazid Preventive Therapy; ART-antiretroviral therapy; CPT-Cotrimoxazole Preventive Therapy; WHO-World Health Organization; HIV-Human Immunodeficiency
virus.
doi:10.1371/journal.pone.0104557.t002
Beneficial Effect of IPT and ART among PLHIV in Ethiopia
PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e104557











Total 295 11290 2.6
Age (years) ,15 23 1099 2.1 1
15–49 253 9624 2.6 1.24 (0.81–1.91)
.49 19 568 3.3 1.61 (0.87–2.95)
Sex Female 139 6705 2.1 1 1
Male 156 4585 3.4 1.57 (1.25–1.97) 1.42 (1.13–1.79)
CPT status No 16 1546 1.0 1
Yes 279 9745 2.9 3.16 (1.90–5.23) 2.15 (1.25–3.69)
WHO Stage Stage 1 or 2 74 6468 1.1 1 1
Stage 3 or 4 221 4822 4.6 4.05 (3.11–5.28) 3.80 (2.87–5,04)
Baseline CD4 ,100 93 2017 4.6 1 1
100–199 82 3537 2.3 0.54 (0.40–0.73) 0.70 (0.52–0.95)
201–349 84 3343 2.5 0.59 (0.44–0.80) 0.59 (0.43–0.81)
.349 36 2394 1.5 0.32 (0.22–0.47) 0.36 (0.23–0.56)
IPT Intake &
completion*
No IPT 244 3969 6.1 1 1
IPT Completion 16 1975 0.8 0.14 (0.08–0.23) 0.15 (0.09–0.26)
IPT non-completion 35 5347 0.7 0.12 (0.08–0.17) 0.13 (0.09–0.19)
Duration on ART* No ART 136 3505 3.9 1 1
0–5 months 76 952 8.0 0.90 (0.65–1.25) 0.38 (0.27–0.54)
6–24 months 45 2868 1.6 0.76 (0.49–1.19) 0.30 (0.19–0.48)
25–42 months 25 2519 1.0 0.43 (0.23–0.82) 0.15 (0.08–0.28)
.42 months 13 1445 0.9 0.37 (0.14–0.95) 0.10 (0.04–0.27)
IPT and/or ART* No intervention 124 2306 5.4 1 1
IPT only 12 1199 1.0 0.24 (0.13–0.44) 0.36 (0.19–0.66)
IPT before ART 6 682 0.9 0.25 (0.11–0.59) 0.18 (0.08–0.42)
ART only 129 3832 3.4 0.74 (0.58–0.96) 0.32 (0.24–0.43)
IPT & ART Simultaneously 8 558 1.4 0.36 (0.17–0.74) 0.20 (0.10–0.42)
IPT after ART 16 2713 0.6 0.19 (0.11–0.34) 0.08 (0.05–0.15)
*Controlled for sex, WHO stage, baseline CD4, and Cotrimoxazole status; HR-Hazard Ratio; CI- Confidence Interval; IPT-Isoniazid Preventive Therapy; ART-antiretroviral
therapy; CPT-Cotrimoxazole Preventive Therapy; WHO-World Health Organization; HIV-Human Immunodeficiency virus.
doi:10.1371/journal.pone.0104557.t003
Table 4. Sensitivity analysis for effectiveness of IPT with or without ART using Cox proportional hazards model among patients on
ART assuming those who were lost to follow-up and dead developed TB in SNNP region, Ethiopia, September 2007 to August 2010.







IPT and/or ART* No intervention 93 1018 9.1 1 1
IPT only 9 370 2.4 0.36 (0.18–0.71) 0.40 (0.20–0.80)
IPT before ART 15 682 2.2 0.42 (0.24–0.74) 0.45 (0.25–0.80)
ART only 266 3832 6.9 0.93 (0.73–1.19) 0.69 (0.53–0.89)
IPT & ART Simultaneously 14 558 2.5 0.39 (0.22–0.70) 0.35 (0.20–0.62)
IPT after ART 41 2713 1.5 0.30 (0.20–0.46) 0.22 (0.15–0.34)
*Controlled for sex, WHO stage, cotrimoxazole use, and baseline CD4; HR-Hazard Ratio; CI- Confidence Interval; IPT-Isoniazid Preventive Therapy; ART-antiretroviral
therapy; WHO-World Health Organization; HIV-Human Immunodeficiency virus.
doi:10.1371/journal.pone.0104557.t004
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protective effect of IPT was comparable to those studies with
positive TST status [4].
Patients ever started on cotrimoxazole were found to be at
higher risk for TB. This is not surprising, considering that those
with advanced immune-suppression who were eligible for it would
have also been at risk for TB [4,11].The association persisted even
after controlling for other potential confounding variables.
This study has implications for policy and practice. We now
have additional data on the effectiveness of IPT in preventing TB
in routine care setting. A simple modeling indicates that, tripling
the IPT coverage in two year time in the study region from the
current level following the recommended IPT initiation would
reduce the number of TB patients among PLHIV in care by 27%
than if no more patients were initiated on IPT after this (Text S1).
This should help convince health workers, patients, and policy
makers in quickly addressing the IPT implementation challenges
to harness its benefit [16]. The potential benefit of initiating IPT
before ART or simultaneously with ART if coupled with effective
implementation of TB screening could reduce TB burden in the
first six months of ART intake. The IPT coverage in this cohort of
HIV infected patients is over twice the national average of 18% for
HIV infected patients in chronic care in Ethiopia [1,17,18] but the
coverage rate was slightly lower in children. This suggests the need
to look for and address additional underlying factors that lead to
lower IPT use rate in the pediatric population in particular and the
PLHIV in general. A study done in South Africa indicates that
lack of knowledge and experience among providers about TB
screening and IPT use as well as lack of awareness of benefits of
IPT among patients contributed to low IPT use [19]. IPT use for
those with advanced HIV disease was found to be lower as
comparable to those with less advanced disease. But since the risk
for TB is higher in this group, IPT use should have been relatively
higher as well. Initiating more patients as such could be
challenging due to higher rates of symptomatic patients in this
group and the difficulty faced by health care workers in excluding
active TB. Late presentation of patients to chronic HIV care adds
to this burden [16]. This is another reminder for the need to have
feasible, improved, and less expensive diagnostic methods in such
settings.
There are several points that make the finding of this study
important. The study showed the level to which IPT intervention
was scaled up and the resultant effectiveness on reduction of TB
risk. The study was done in routine clinical care setting in a low-
income country and this will add to the limited evidence of IPT
effectiveness under such conditions. A previous study done in
Ethiopia on factors affecting occurrence of TB showed IPT use
prevented TB (adjusted odds ratio 0.35). Similar assessments were
done in Brazil and South Africa and comparable results were
documented in the effectiveness of IPT with ART while IPT
coverage (10 and 13% respectively) and effectiveness of ‘IPT only’
(43 and 13% respectively) were much lower than the findings from
our study [5,6]. In a different study in Tanzania, IPT was not
found to be effective at all [20]. Our study presents new evidence
on the effect of timing of IPT initiation with respect to ART.
There are ongoing clinical trials looking into this which will clear
uncertainties [21].
Although coverage of IPT for this cohort of HIV infected
patients was lower than the expected, it was more than twice the
prior estimate for the national average of 18% among HIV
infected patients in chronic care [1,17,18]. The coverage is even
higher for patients ever started on ART. It was also better than
reported coverage in other African countries such as Mozambique
(,1%); but lower than that of South Africa where it was 46% in
2011 [22,23]. The relatively better IPT coverage rate in this
cohort could be attributed to the technical support provided by
JHU TSEHAI, a PEPFAR-supported program, which involved
monthly site-level mentoring, training health care providers, IPT-
focused update sessions, and improved data capturing system.
Long-term ART was associated with greater reduction of risk of
TB in this study. The result is comparable to a study done in South
Africa that found that TB risk decreased significantly with long-
term ART treatment although it remained at four times the risk to
the general population [7]. Findings of higher TB incidence in the
early months of ART in this study were similar to findings from a
large multinational cohort study in six sub-Saharan African
countries with TB incidence in the first three months being 13
per 100 PY, a bit higher than TB incidence in Pre-ART period at
10.5 per 100 PY [24].
Our findings should be interpreted cautiously because of some
important limitations. Missing data and incomplete documenta-
tion were the major limitations for some variables. Missing data for
baseline CD4 and WHO stage were accounted for by imputation.
IPT completion was documented in 24% of the records only,
which did not allow for thorough comparison on the effect of IPT
by adherence rate. Being on ART was associated with higher
completion of IPT in Brazil [24], for example, but this was not
demonstrated in the present study. Also, because of the limited
number of variables in the database, we were not able to include
variables such as anemia and body-mass index in our analyses. TB
diagnosis was presumptive or was based on sputum and chest x-
ray results in most cases, which might have led to over or under
estimation of the actual number of TB cases. Patients who were
lost to follow-up or died had lower CD4 counts and more
advanced WHO disease stage putting them at greater risk for TB
as compared to those active in follow-up. Hence, TB incidence
was likely to be a bit higher in this study population.
The strengths of this study include that it was adequately
powered to study the relationship between the effect of ART used
alone and with IPT in reducing TB because of large sample size
and adequate number of events. Since all study records were
included the potential for selection bias was reduced.
Conclusions
This study indicates that IPT intake in addition to ART could
be beneficial in reducing risk of TB among PLHIV in high TB and
HIV setting in resource-limited countries. The most benefit would
be harnessed if IPT was initiated before or at the same time with
ART. The gap in IPT coverage should be addressed urgently and
in particular children less than 14 years with HIV that represent a
group at significant risk for TB must be prioritized. Further studies
are needed to assess the level of adherence, and barriers to IPT
provision.
Supporting Information
Figure S1 Splitting of subjects according to time-
updated. Coding of time updated variables: ART=0 means
ART not received; ART=1 means ART received; IPT= 0 means
IPT not received; IPT=1 means IPT received; Subject 1 received
no intervention for nine years for which reason value of both ART
and IPT was set to ‘0’ for the whole duration. Subject 2 received
no intervention for the first three years but after that IPT was
received and stayed in care for seven years. So the value of IPT
was updated to ‘1’ in the period where IPT was received. Subject 3
received no intervention for the first three years but after that
ART was received and stayed in care for six years. So the value of
ART was updated to ‘1’ in the period where ART was received.
Subject 4 received no intervention for the first four years, took IPT
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for three years followed by initiation of ART. In the period ART
was initiated, this subjected was exposed for the effects of both
ART and IPT for three years but with the effect of IPT coming
first. So the value of IPT was updated to ‘1’ in the period where
IPT only was received, then after ART initiation, both values of
ART and IPT was made to be ‘1’. Subject 5 experienced the same
chain of events as in Subject 4, except ART initiation preceded
IPT initiation. Subject 6 received no intervention for the first five
years followed by initiation of both ART and IPT at the same time
and stayed in care for five years. For this reason, value of ART and
IPT was updated to ‘1’ at the same time. Subjects 2–5 contributed
person-time of follow-up to more than one treatment category.
(TIF)
Text S1 Estimated effect of IPT scale-up on incidence of
TB/HIV co-infection.
(DOCX)
Supporting Information S1 Dataset and program codes.
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